Comparative Pharmacology
Head-to-head clinical analysis: OHTUVAYRE versus PREDNISOLONE EYE DROPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OHTUVAYRE versus PREDNISOLONE EYE DROPS.
OHTUVAYRE vs Prednisolone Eye Drops
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OHTUVAYRE is an antisense oligonucleotide that binds to the survival motor neuron 2 (SMN2) pre-mRNA, altering splicing to increase production of full-length survival motor neuron (SMN) protein.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression and suppressing inflammatory mediators such as prostaglandins and leukotrienes.
OHTUVAYRE (vadadustat) is administered orally at a starting dose of 300 mg once daily. The dose may be titrated based on hemoglobin response in increments of 150 mg up to a maximum of 600 mg once daily.
Instill 1-2 drops into the conjunctival sac of the affected eye(s) four times daily. In severe cases, dosing may be initiated with 1-2 drops every 1-2 hours and tapered upon improvement.
None Documented
None Documented
Terminal elimination half-life is approximately 20 hours (range 15-25 h), supporting once-daily dosing.
Plasma: 2-4 hours; tissue effects persist 18-36 hours. Clinically, duration of adrenal suppression may exceed plasma half-life.
Primarily renal excretion as unchanged drug: 70-80% in urine, with approximately 20% in feces via biliary elimination.
Renal (primarily as metabolites): ~70% after oral dose; unchanged drug: <20%. Biliary/fecal: minor.
Category C
Category A/B
Ophthalmic Corticosteroid
Ophthalmic Corticosteroid